Bengaluru : Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that Health Canada has granted a Notice of Compliance (NOC) for Yesintek (ustekinumab injection) and Yesintek I.V. (ustekinumab for injection, solution for intravenous infusion), biosimilars to Stelara (ustekinumab injection) and Stelara I.V.

The approval, granted on October 17, 2025, clears the path for commercial availability in mid-October across Canada.

YESINTEK and YESINTEK I.V. are indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients (6–17 years), active psoriatic arthritis in adults, and moderately to severely active Crohn’s disease and ulcerative colitis in adults — autoimmune diseases affecting thousands of Canadians.

Health Canada’s decision was bas

See Full Page